Literature DB >> 27576360

Computed tomography imaging assessment of postexternal beam radiation changes of the liver.

Michael Lock1, Ashkan A Malayeri2, Omar Y Mian3, Nina A Mayr4, Joseph M Herman3, Simon S Lo4.   

Abstract

Radiation is being used for patients with primary and secondary liver cancers, as a rapidly evolving treatment. However, postradiation imaging changes of the liver are not well understood and therefore challenging to interpret. Distinguishing normal radiation changes from residual or recurrent disease is difficult. Size and contrast enhancement have been used to guide interpretation and clinical recommendations, but normal radiation changes can make interpretation difficult and are not accounted for in available guidelines. Knowledge of dose- and time-dependent changes in addition to imaging findings, such as morphological and enhancement patterns, provides useful differentiating parameters. This paper reviews recent studies using computed tomography that can guide interpretation and help differentiate tumor from benign changes after external beam radiation.

Entities:  

Keywords:  hepatocellular carcinoma; radiation therapy/radiotherapy; stereotactic radiotherapy

Mesh:

Year:  2016        PMID: 27576360      PMCID: PMC5551926          DOI: 10.2217/fon-2016-0165

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  34 in total

Review 1.  Diffusion and perfusion MRI: basic physics.

Authors:  R Luypaert; S Boujraf; S Sourbron; M Osteaux
Journal:  Eur J Radiol       Date:  2001-04       Impact factor: 3.528

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

Review 3.  Imaging changes after stereotactic body radiation therapy for lung and liver tumors.

Authors:  Simon S Lo; Bin S Teh; Jian Z Wang; Zhibin Huang; Jennifer Zook; Tracy Price; Nina A Mayr; John C Grecula; Robert D Timmerman; Higinia R Cardenes
Journal:  Expert Rev Anticancer Ther       Date:  2011-04       Impact factor: 4.512

Review 4.  Motion management in gastrointestinal cancers.

Authors:  Hassan Abbas; Bryan Chang; Zhe Jay Chen
Journal:  J Gastrointest Oncol       Date:  2014-06

Review 5.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

6.  Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.

Authors:  Juan C Camacho; Nima Kokabi; Minzhi Xing; Hasmukh J Prajapati; Bassel El-Rayes; Hyun S Kim
Journal:  J Vasc Interv Radiol       Date:  2014-02       Impact factor: 3.464

7.  Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.

Authors:  Michael Vouche; Laura Kulik; Rohi Atassi; Khairuddin Memon; Ryan Hickey; Daniel Ganger; Frank H Miller; Vahid Yaghmai; Michael Abecassis; Talia Baker; Mary Mulcahy; Ritu Nayar; Robert J Lewandowski; Riad Salem
Journal:  Hepatology       Date:  2013-10-01       Impact factor: 17.425

8.  Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?

Authors:  Alejandro Forner; Carmen Ayuso; María Varela; Jordi Rimola; Amelia J Hessheimer; Carlos Rodriguez de Lope; María Reig; Luís Bianchi; Josep M Llovet; Jordi Bruix
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

9.  The triple-phase CT image appearance of post-irradiated livers.

Authors:  S Y Chiou; R C Lee; K H Chi; J Chia-Hsien Cheng; J H Chiang; C Y Chang
Journal:  Acta Radiol       Date:  2001-09       Impact factor: 1.701

10.  Stereotactic body radiotherapy-induced arterial hypervascularity of non-tumorous hepatic parenchyma in patients with hepatocellular carcinoma: potential pitfalls in tumor response evaluation on multiphase computed tomography.

Authors:  Mee Jin Park; So Yeon Kim; Sang Min Yoon; Jong Hoon Kim; Seong Ho Park; Seung Soo Lee; Yedaun Lee; Moon-Gyu Lee
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

View more
  3 in total

1.  FDG-Avid Focal Liver Reaction From Proton Therapy in a Patient With Primary Esophageal Adenocarcinoma.

Authors:  Hena S Ahmed; Austin R Pantel; James M Metz; John P Plastaras; Michael D Farwell
Journal:  Clin Nucl Med       Date:  2018-05       Impact factor: 7.794

Review 2.  Imaging Evaluation Following 90Y Radioembolization of Liver Tumors: What Radiologists Should Know.

Authors:  Ijin Joo; Hyo-Cheol Kim; Gyoung Min Kim; Jin Chul Paeng
Journal:  Korean J Radiol       Date:  2018-02-22       Impact factor: 3.500

3.  Indicator for local recurrence of hepatocellular carcinoma after proton beam therapy: analysis of attenuation difference between the irradiated tumor and liver parenchyma on contrast enhancement CT.

Authors:  Hiroaki Takahashi; Yuta Sekino; Kensaku Mori; Toshiyuki Okumura; Katsuhiro Nasu; Kuniaki Fukuda; Sota Masuoka; Takashi Iizumi; Naoyuki Hasegawa; Hideyuki Sakurai; Manabu Minami
Journal:  Br J Radiol       Date:  2019-11-07       Impact factor: 3.039

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.